A computer model of two drugs that reach the brain
Original title: Physiologically based pharmacokinetic model of two ALK inhibitors to inform drug and dosing regimens for brain metastasis patients.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was done on cells in a lab, not in people. It is a very early step.
This was a computer model, not a new test in people.
The short version
Researchers used a computer model to study drug doses for tumors that spread to the brain.
What was studied. Researchers built computer models of two drugs, brigatinib and lorlatinib. The models guessed how much of each drug reaches the blood and the fluid around the brain. The guesses were checked against data from past patient studies.
What they found. The model's guesses closely matched the real patient data. For brigatinib, only higher doses of 240 mg once a day or 180 mg twice a day hit the target for blocking certain gene changes. Lorlatinib hit the target for all eight gene changes at 50 mg twice a day or 100 mg once a day.
What this means, and what it doesn't
What it could mean: This is a planning tool for researchers and doctors. In time, it may help them pick doses more likely to reach the brain. It does not change anyone's treatment today. Dose choices stay a decision for your own care team.
What it doesn't mean: This does not mean a new treatment is here. No one was given a new drug or a new dose in this study. It was a computer model built from data that already existed. It does not show that any dose works better or is safer for patients. It is not a cure, and it is a long way from everyday care.
Source: PubMed, July 30, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.